NURIX THERAPEUTICS, INC. Payments to Acquire Marketable Securities
NURIX THERAPEUTICS, INC. (NRIX) reported Payments to Acquire Marketable Securities of $280.56 million for the 6-month period ending 2026-05-31, per its 10-Q filed 2026-07-09.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-07-09
- NURIX THERAPEUTICS, INC. payments to acquire marketable securities for the quarter ending 2026-05-31 was $24.63M, a 63.87% decline year-over-year.
- NURIX THERAPEUTICS, INC. payments to acquire marketable securities for the quarter ending 2026-02-28 was $255.93M, a 132.28% increase year-over-year.
- NURIX THERAPEUTICS, INC. payments to acquire marketable securities for the quarter ending 2025-11-30 was $174.34M, a 41.54% decline year-over-year.
- NURIX THERAPEUTICS, INC. payments to acquire marketable securities for the quarter ending 2025-08-31 was $103.00M, a 20.66% decline year-over-year.
- NURIX THERAPEUTICS, INC. payments to acquire marketable securities for fiscal 2025 was $455.69M, a 35.63% decline from fiscal 2024.
- NURIX THERAPEUTICS, INC. payments to acquire marketable securities for fiscal 2024 was $707.95M, a 187.40% increase from fiscal 2023.
- NURIX THERAPEUTICS, INC. payments to acquire marketable securities for fiscal 2023 was $246.33M, a 2.91% increase from fiscal 2022.
- NURIX THERAPEUTICS, INC. payments to acquire marketable securities for fiscal 2022 was $239.37M.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-05-31 | $24.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-09 | $280.56M 10-Q · filed 2026-07-09 | $454.90M derived: sum of 3 quarters · filed 2026-07-09 | $557.90M derived: sum of 4 quarters · filed 2026-07-09 |
| 2026-02-28 | $255.93M 10-Q · filed 2026-04-08 | $430.27M derived: sum of 2 quarters · filed 2026-04-08 | $533.27M derived: sum of 3 quarters · filed 2026-04-08 | $601.44M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-11-30 | $174.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $277.34M derived: sum of 2 quarters · filed 2026-01-28 | $345.50M derived: sum of 3 quarters · filed 2026-07-09 | $455.69M 10-K · filed 2026-01-28 |
| 2025-08-31 | $103.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-09 | $171.17M derived: sum of 2 quarters · filed 2026-07-09 | $281.35M 10-Q · filed 2025-10-09 | $579.57M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-05-31 | $68.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-09 | $178.35M 10-Q · filed 2026-07-09 | $476.57M derived: sum of 3 quarters · filed 2026-07-09 | $606.38M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-02-28 | $110.18M 10-Q · filed 2026-04-08 | $408.40M derived: sum of 2 quarters · filed 2026-04-08 | $538.22M derived: sum of 3 quarters · filed 2026-04-08 | $763.33M derived: sum of 4 quarters · filed 2026-04-08 |
| 2024-11-30 | $298.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $428.03M derived: sum of 2 quarters · filed 2026-01-28 | $653.15M derived: sum of 3 quarters · filed 2026-01-28 | $707.95M 10-K · filed 2026-01-28 |
| 2024-08-31 | $129.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-09 | $354.94M derived: sum of 2 quarters · filed 2025-10-09 | $409.74M 10-Q · filed 2025-10-09 | $498.13M derived: sum of 4 quarters · filed 2026-01-28 |
| 2024-05-31 | $225.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-09 | $279.92M 10-Q · filed 2025-07-09 | $368.31M derived: sum of 3 quarters · filed 2026-01-28 | $442.90M derived: sum of 4 quarters · filed 2026-01-28 |
| 2024-02-29 | $54.80M 10-Q · filed 2025-04-08 | $143.20M derived: sum of 2 quarters · filed 2026-01-28 | $217.78M derived: sum of 3 quarters · filed 2026-01-28 | $278.50M derived: sum of 4 quarters · filed 2026-01-28 |
| 2023-11-30 | $88.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $162.98M derived: sum of 2 quarters · filed 2026-01-28 | $223.69M derived: sum of 3 quarters · filed 2026-01-28 | $246.33M 10-K · filed 2026-01-28 |
| 2023-08-31 | $74.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-11 | $135.30M derived: sum of 2 quarters · filed 2024-10-11 | $157.94M 10-Q · filed 2024-10-11 | $184.85M derived: sum of 4 quarters · filed 2025-01-28 |
| 2023-05-31 | $60.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-11 | $83.35M 10-Q · filed 2024-07-11 | $110.26M derived: sum of 3 quarters · filed 2025-01-28 | $242.69M derived: sum of 4 quarters · filed 2025-01-28 |
| 2023-02-28 | $22.64M 10-Q · filed 2024-04-10 | $49.55M derived: sum of 2 quarters · filed 2025-01-28 | $181.98M derived: sum of 3 quarters · filed 2025-01-28 | $246.76M derived: sum of 4 quarters · filed 2025-01-28 |
| 2022-11-30 | $26.91M derived: 10-K 12 month − 10-Q 9 month · filed 2025-01-28 | $159.34M derived: sum of 2 quarters · filed 2025-01-28 | $224.12M derived: sum of 3 quarters · filed 2025-01-28 | $239.37M 10-K · filed 2025-01-28 |
| 2022-08-31 | $132.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-12 | $197.21M derived: sum of 2 quarters · filed 2023-10-12 | $212.46M 10-Q · filed 2023-10-12 | |
| 2022-05-31 | $64.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-13 | $80.03M 10-Q · filed 2023-07-13 | ||
| 2022-02-28 | $15.24M 10-Q · filed 2023-04-13 | |||
| 2021-08-31 | $257.81M 10-Q · filed 2022-10-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |